Pancreatic Cancer Research

ResearcherThe University of OsakaActive in the last 2 years

Yoshikatsu Kanai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8126-286X; OpenAlex author ID A5103043727. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 4

  1. Upregulation of ATF4 mediates the cellular adaptation to pharmacologic inhibition of amino acid transporter LAT1 in pancreatic ductal adenocarcinoma cells. Last author DOI 10.1016/j.jphs.2024.03.001↗
  2. Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00280-017-3477-4↗
  3. Relationship between CD147 and expression of amino acid transporters (LAT1 and ASCT2) in patients with pancreatic cancer. Co-author PMID 25901202↗
  4. Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. Co-author DOI 10.1038/bjc.2012.310↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yu Ma · 1 shared paper, 2024 · strength 0.23
  2. Kyoichi Kaira · 3 shared papers, 2012–2018 · strength 0.15
  3. Izumi Takeyoshi · 2 shared papers, 2012–2015 · strength 0.08
  4. Bolag Altan · 1 shared paper, 2018 · strength 0.07
  5. Akira Watanabe Watanabe · 1 shared paper, 2018 · strength 0.07
  6. Kenichiro Araki · 1 shared paper, 2018 · strength 0.07
  7. Hiroyuki Kuwano · 1 shared paper, 2018 · strength 0.07
  8. Takehiko Yokobori · 1 shared paper, 2018 · strength 0.07
  9. Ken Shirabe · 1 shared paper, 2018 · strength 0.07
  10. Masatomo Mori · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.